Daratumumab, Carfilzomib, Lenalidomide and Low Dose Dexamethasone (DKRd) in Newly Diagnosed, Multiple Myeloma
Summary
Third Opinion Trial Synopsis:
This study wants to find out how patients with a disease called multiple myeloma respond to a treatment called D-KRd. They will be studying the patients after 8 cycles of this treatment.
This study wants to find out how patients with a disease called multiple myeloma respond to a treatment called D-KRd. They will be studying the patients after 8 cycles of this treatment.
*Third Opinion AI Generated Synopsis
Trial Summary
The purpose of this study is to determine response rate after 8 cycles of D-KRd (daratumumab, carfilzomib, lenalidomide (Revlimid) and dexamethasone in patients with multiple myeloma.
The purpose of this study is to determine response rate after 8 cycles of D-KRd (daratumumab, carfilzomib, lenalidomide (Revlimid) and dexamethasone in patients with multiple myeloma.
Locations & Contact
Fill out the form and "Notify Multiple Myeloma Research Foundation" to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts:
